HIPRA-HH-2, NCT05142553 / 2021-005226-26: Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. |
|
|
| Completed | 2 | 887 | Europe | COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech) | Hipra Scientific, S.L.U, Laboratorios Hipra, S.A. | COVID-19, SARS-CoV-2 Acute Respiratory Disease | 05/23 | 05/23 | | |
